首页>投融资
Enveda Biosciences
未公开
Enveda Biosciences is a biotechnology company engineering new drugs from plants. Its platform applies cutting-edge advancements in knowledge graphs, metabolomics, and machine learning to discover the next generation of small molecule therapeutics.In April 2023, Enveda Biosciences closed an additional $51 million equity financing to add to the $68 million Series B announced in December 2022.In December 2022, the company closed an equity and debt financing of $68-million.In June 2021, Enveda Biosciences announced an oversubscribed $51M Series A funding round
基本信息
-
公司全称Enveda Biosciences Inc
-
类型小分子疗法研发商
-
产业领域药品研发/制造、化学药、研发制造服务
-
公司人数15~50人
-
地址1880 S Flatiron Court,Ste K, BOULDER COLORADO 80301; US; Telephone: +14153235252;
-
联系电话+1-415-323-5252
-
邮箱info@envedabio.com
-
成立时间2019-01-01
投融资
-
2024-06-14未公开5500万美元PremjiInvestLingotto Investment FundMicrosoft ResearchKinnevikTrue VenturesFPV VenturesLevel VenturesJazz Venture
-
2023-04-20股权融资5100万美元FPV VenturesTrue VenturesWireframe VenturesDimension CapitalKinnevik
-
2022-12-21B轮6800万美元Dimension CapitalAllen & CompanyTwo Sigma VenturesHummingbirdWireframe VenturesLux CapitalTrue VenturesPossible VenturesAmino CollectiveLevel VenturesJazz VentureFPV Ventures
-
2022-12-21债权融资未透露美国硅谷银行
-
2021-06-22A轮5100万美元HummingbirdCatalio Capital ManagementLux CapitalTrue VenturesLifeForce CapitalVillage GlobalWireframe VenturesTwo Sigma Ventures
-
2020-10-16种子轮490万美元Village GlobalTrue VenturesWireframe Ventures
- 加载更多
相关投融资企业
B轮
Iambic Therapeutics成立于2019年，总部位于加利福尼亚州拉霍亚，凭借其独特的人工智能驱动的药物发现平台颠覆了治疗领域。Iambic组建了一支世界级的团队，将开创性的人工智能专家和经验丰富的药物猎人联合起来，他们在提供临床验证的治疗方法方面有着良好的成功记录。Iambic平台已被证明能够以前所未有的速度为临床提供高质量、差异化的疗法，并跨越多个靶点类别和作用机制。Iambic团队正在推进临床资产的内部pipeline，以解决未满足的紧急患者需求。在 iambic.ai 上了解有关 Iambic 团队、平台和管道的更多信息。
未公开
Enveda Biosciences is a biotechnology company engineering new drugs from plants. Its platform applies cutting-edge advancements in knowledge graphs, metabolomics, and machine learning to discover the next generation of small molecule therapeutics.In April 2023, Enveda Biosciences closed an additional $51 million equity financing to add to the $68 million Series B announced in December 2022.In December 2022, the company closed an equity and debt financing of $68-million.In June 2021, Enveda Biosciences announced an oversubscribed $51M Series A funding round
B轮
Iambic Therapeutics成立于2019年，总部位于加利福尼亚州拉霍亚，凭借其独特的人工智能驱动的药物发现平台颠覆了治疗领域。Iambic组建了一支世界级的团队，将开创性的人工智能专家和经验丰富的药物猎人联合起来，他们在提供临床验证的治疗方法方面有着良好的成功记录。Iambic平台已被证明能够以前所未有的速度为临床提供高质量、差异化的疗法，并跨越多个靶点类别和作用机制。Iambic团队正在推进临床资产的内部pipeline，以解决未满足的紧急患者需求。在 iambic.ai 上了解有关 Iambic 团队、平台和管道的更多信息。
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息